The Challenge of Postoperative Central Neuropathic Pain

Postoperative central neuropathic pain represents a debilitating complication following spinal cord surgery. Patients frequently describe severe burning, allodynia, dysesthesia, and lancinating shock-like sensations that resist conventional interventions. Although surgical decompression relieves structural spinal compression, secondary neuroinflammatory cascades often drive central sensitization. Consequently, clinicians routinely initiate first-line gabapentinoids such as gabapentin and pregabalin to dampen aberrant spinal signaling. However, a significant proportion of patients experience persistent symptoms or develop dose-limiting adverse effects. In these refractory cases, clinicians face considerable therapeutic challenges because alternative non-opioid options remain scarce. Recently, prescribing mirogabalin for neuropathic pain has gained significant clinical interest as a potential salvage strategy. Mirogabalin provides a unique binding profile that may overcome the pharmacodynamic limitations of older calcium channel ligands. Nevertheless, real-world data evaluating its therapeutic efficacy in postoperative spinal cord injury patients remain limited. Clinicians need robust evidence to determine whether switching agents can re-establish pain control. Therefore, evaluating real-world patient outcomes provides indispensable guidance for spine surgeons, neurologists, and pain specialists seeking to optimize postoperative analgesia.

Pharmacological Profile of Mirogabalin for Neuropathic Pain

Mirogabalin operates as a potent, selectively targeted ligand for voltage-gated calcium channels. Similar to first-generation gabapentinoids, the molecule binds the alpha-2-delta-1 and alpha-2-delta-2 auxiliary subunits. However, mirogabalin displays substantially higher binding affinity and slower dissociation kinetics at the alpha-2-delta-1 subunit. Because the alpha-2-delta-1 subtype modulates pain pathways, this sustained inhibition produces potent analgesic efficacy. Conversely, mirogabalin dissociates rapidly from the alpha-2-delta-2 subunit, which mediates unwanted central adverse effects like somnolence and ataxia. Consequently, this kinetic selectivity offers a broader therapeutic window than pregabalin or gabapentin. Furthermore, mirogabalin exhibits predictable linear pharmacokinetics with excellent oral bioavailability. Unlike gabapentin, which relies on saturable gastrointestinal transport carriers, mirogabalin absorption remains consistent across therapeutic doses. Clinicians can therefore achieve dependable plasma drug levels without erratic systemic exposure. For patients suffering from refractory spinal cord-related pain, this refined molecular pharmacology provides a strong rationale for switching medications. Moreover, international phase 3 clinical trials have confirmed robust analgesia in peripheral neuropathic disorders. Thus, mirogabalin represents an innovative therapeutic tool for challenging neuropathic conditions.

Real-World Analgesic Efficacy and Responder Rates

A recent observational study examined forty-one surgical patients who switched to mirogabalin after failing conventional gabapentinoids. Every participant experienced inadequate pain control despite prior gabapentin or pregabalin administration. Researchers evaluated patient-reported outcomes, designating a pain reduction of thirty percent or more as clinically meaningful and fifty percent or more as substantial. Patients entered the study with a mean baseline numerical rating scale pain score of 3.93. Notably, the median duration between spinal surgery and initiating mirogabalin was 411 days, demonstrating long-standing neural chronicity. Following the pharmacotherapeutic transition, 53.7% of patients attained clinically meaningful pain reduction of thirty percent or greater. Additionally, 46.3% achieved substantial pain relief exceeding fifty percent. These findings illustrate that more than half of previously refractory patients experienced noticeable clinical relief. Furthermore, prolonged symptom duration did not prevent successful pain attenuation. Although retrospective designs carry inherent subjectivity, these real-world data confirm meaningful analgesic salvage. Consequently, switching to mirogabalin serves as an effective therapeutic maneuver before physicians consider more invasive interventions.

Safety Profile and Discontinuation Rates

Evaluating treatment safety remains crucial when introducing novel pharmacotherapy to complex spine patients. In the reported cohort, 31.7% of patients experienced treatment-related adverse events during the observation period. Specifically, somnolence occurred in 12.2% of individuals, while dizziness and weight gain affected 7.3% each. Importantly, all observed adverse effects were mild to moderate, and no serious complications occurred. Nevertheless, adverse events prompted 22.0% of patients to discontinue mirogabalin and return to their prior medications. Additionally, 19.5% ceased treatment due to insufficient analgesic response. Overall, more than half of all treated patients maintained continuous mirogabalin therapy with favorable tolerability. These findings demonstrate that clinicians must implement careful, individualized dosing strategies. Because patients with central cord lesions exhibit heightened neurocognitive sensitivity, starting with lower doses helps prevent early discontinuation. Furthermore, clinicians must evaluate baseline renal clearance since mirogabalin undergoes primary urinary excretion. By anticipating common side effects and counseling patients proactively, clinicians can significantly enhance therapeutic adherence.

Clinical Implications Across Tumor and Non-Tumor Etiologies

Spinal cord pathologies encompass distinct structural etiologies that may influence pharmacological responsiveness. In the study, investigators performed subgroup comparisons between patients with spinal tumors and those with non-tumoral compressive myelopathies. Among tumor resection patients, 60.0% achieved clinically meaningful pain reduction after the switch. Similarly, 47.6% of patients with non-tumoral myelopathies attained meaningful pain relief. Statistical comparisons confirmed no significant difference in responder rates between these two cohorts. This observation indicates that mirogabalin alleviates central neuropathic pain regardless of whether the initial insult was neoplastic or degenerative. At the cellular level, dorsal horn hyperexcitability and abnormal calcium influx represent common pathophysiological mechanisms across both groups. Consequently, targeting calcium channel subunits delivers consistent analgesia across heterogeneous surgical presentations. Spine surgeons routinely manage both degenerative spinal conditions and oncologic cord compressions. Therefore, having a single reliable agent that performs consistently across diverse etiologies simplifies postoperative management. Ultimately, mirogabalin expands the non-opioid armamentarium for managing persistent postoperative central pain syndromes.

How does mirogabalin differ from pregabalin and gabapentin?

Mirogabalin possesses a distinct molecular kinetic profile characterized by potent, sustained binding to the alpha-2-delta-1 calcium channel subunit, which primarily mediates pain relief. Conversely, it dissociates more rapidly from the alpha-2-delta-2 subunit, which researchers link to central adverse effects like somnolence. Additionally, mirogabalin provides predictable linear pharmacokinetics with superior oral bioavailability. These combined characteristics often allow clinicians to achieve effective pain control while minimizing dose-limiting neurocognitive side effects.

What proportion of refractory patients respond to a mirogabalin switch?

In clinical observational research, switching to mirogabalin achieved clinically meaningful pain reduction of at least thirty percent in approximately 53.7% of patients with refractory central neuropathic pain. Furthermore, substantial pain relief of fifty percent or greater occurred in 46.3% of individuals. These outcomes demonstrate that roughly half of surgical spine patients who failed traditional gabapentin or pregabalin can experience meaningful symptom alleviation following a planned transition to mirogabalin.

What are the most common adverse events associated with mirogabalin?

The most frequently reported adverse effects during mirogabalin therapy include somnolence, dizziness, and peripheral weight gain. Real-world data indicate that approximately 31.7% of patients report side effects, with somnolence occurring in 12.2% and dizziness in 7.3%. Most adverse events remain mild to moderate in severity. However, roughly 22% of patients may discontinue therapy due to tolerability issues, highlighting the critical importance of slow upward dose titration.

Disclaimer: This content is for informational and educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment when evaluating patients. Refer to the latest local and national guidelines for clinical practice.

References

1. Kim DW et al. Patient-Reported Outcomes of Mirogabalin in Patients with Postoperative Spinal Cord-Related Central Neuropathic Pain Inadequately Controlled with Conventional Gabapentinoids: A Retrospective Real-World Study. J Korean Neurosurg Soc. 2026 Sep 30. doi: 10.3340/jkns.2026.0149. PMID: 42812110.


2. Baba H, et al. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia. Neurology. 2023;100(11):e1193-e1204.


3. Kato J, et al. Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia. Pain Ther. 2023;12(3):813-829.